There is emerging evidence both locally and internationally of an association between certain breast implants and the risk of a rare cancer known as breast implant anaplastic large cell lymphoma (BIA-ALCL). The Therapeutic Goods Administration (TGA) continues to review and assess all of the breast implants available in the Australian market.
In August, Allergan voluntarily recalled their un-implanted Biocell macro-textured breast implants and tissue expanders and Emergo also cancelled their Airxpanders Aeroform tissue expanders.
In September, the TGA published its decision to recall and suspend a number of other breast implants and tissue expanders. Updates on the breast implant recall and suspension and the full list of recalled and suspended products can be found at the TGA’s Breast Implant Hub.
BIA-ALCL is a rare form of non–Hodgkins lymphoma. It is not breast cancer, which forms from cells in the breast, but a cancer of the lymphatic system. The most common presenting symptoms are breast asymmetry, pain, delayed effusion or seroma, or, less commonly, a mass or lymphadenopathy. The TGA has published fact sheets for both health professionals and consumers.
Patients can also call HealthDirect on 1800 022 222 for further information.